Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Articles by Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Latest Updated Articles
- Study Summary: Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis
Published: August 13th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Medicaid Work Requirements Set to Leave Millions Without Insurance
2
Most Favored Nation Drug Pricing Moves Forward, but Experts Warn Details Are Still Missing
3
AMCP Nexus 2025: Advancing Health Policy and Patient Outcomes Together
4
Oncology Landscape Continues to Evolve With Expanded Indications, First-in-Class Therapies
5
